These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26009615)

  • 1. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.
    McIlleron H; Abdel-Rahman S; Dave JA; Blockman M; Owen A
    J Infect Dis; 2015 Jun; 211 Suppl 3(Suppl 3):S115-25. PubMed ID: 26009615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
    Regazzi M; Carvalho AC; Villani P; Matteelli A
    Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.
    Rabie H; Decloedt EH; Garcia-Prats AJ; Cotton MF; Frigati L; Lallemant M; Hesseling A; Schaaf HS
    Expert Opin Pharmacother; 2017 Apr; 18(6):589-598. PubMed ID: 28346018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
    Schluger NW
    Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current research toward optimizing dosing of first-line antituberculosis treatment.
    McIlleron H; Chirehwa MT
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):27-38. PubMed ID: 30501530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication errors with antituberculosis therapy in an inpatient, academic setting: forgotten but not gone.
    Jen SP; Zucker J; Buczynski P; Odenigbo C; Cennimo D; Patrawalla A
    J Clin Pharm Ther; 2016 Feb; 41(1):54-8. PubMed ID: 26763664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.
    Gupta A; Mathad JS; Abdel-Rahman SM; Albano JD; Botgros R; Brown V; Browning RS; Dawson L; Dooley KE; Gnanashanmugam D; Grinsztejn B; Hernandez-Diaz S; Jean-Philippe P; Kim P; Lyerly AD; Mirochnick M; Mofenson LM; Montepiedra G; Piper J; Sahin L; Savic R; Smith B; Spiegel H; Swaminathan S; Watts DH; White A
    Clin Infect Dis; 2016 Mar; 62(6):761-769. PubMed ID: 26658057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis and HIV co-infection: a practical therapeutic approach.
    Breen RA; Swaden L; Ballinger J; Lipman MC
    Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.
    Chabala C; Turkova A; Thomason MJ; Wobudeya E; Hissar S; Mave V; van der Zalm M; Palmer M; Kapasa M; Bhavani PK; Balaji S; Raichur PA; Demers AM; Hoddinott G; Owen-Powell E; Kinikar A; Musoke P; Mulenga V; Aarnoutse R; McIlleron H; Hesseling A; Crook AM; Cotton M; Gibb DM;
    Trials; 2018 Apr; 19(1):237. PubMed ID: 29673395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric tuberculosis: global overview and challenges.
    Swaminathan S; Rekha B
    Clin Infect Dis; 2010 May; 50 Suppl 3():S184-94. PubMed ID: 20397947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
    Semvua HH; Kibiki GS; Kisanga ER; Boeree MJ; Burger DM; Aarnoutse R
    Ther Drug Monit; 2015 Feb; 37(1):22-32. PubMed ID: 24943062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa.
    Pallerla SR; Elion Assiana DO; Linh LTK; Cho FN; Meyer CG; Fagbemi KA; Adegnika AA; Beng VP; Achidi EA; Kahunu GM; Bates M; Grobusch MP; Kremsner PG; Ntoumi F; Velavan TP
    Int J Infect Dis; 2021 Mar; 104():207-213. PubMed ID: 33310105
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.